Sight Sciences Inc (SGHT) News

Earnings Trend: SGHT is unprofitable, and losses have increased over the past 5 years at a rate of 15.5% per year.

Insider trading , why did:
D1 capital partners LD on 26 Dec23
Sell $16,712,931 of sight sciences?
Entity: company
Shares: 2,852,036
Max Price: $5.86

Sight Sciences Insiders Are Selling The Stock
Over the last three months, we've seen significant insider selling at Sight Sciences. In total, insiders sold US$244k worth of shares in that time, and we didn't record any purchases whatsoever.
Yahoo finance June 14, 2024

Sight Sciences Insiders Are Selling The Stock
Over the last three months, we've seen significant insider selling at Sight Sciences. In total, insiders sold US$244k worth of shares in that time, and we didn't record any purchases whatsoever.
Yahoo finance June 14, 2024

SGHT under $10

Wow- somebody took a bunch of profit in the last minutes. First down day is quite a while

And another up day.

First time SGHT closed above $7 in over 6 months!!!

She broke through seven dollars. very strong volume today. So bright I gotta wear shades

Good news...

creates big gains. Blue skies ahead. My $2.98's have doubled+

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced the publication of the twelve-month results from the SAHARA trial.

Patients previously treated with Restasis® (cyclosporine ophthalmic emulsion 0.05%) prescription eyedrops (“Restasis”) had additional clinically meaningful improvements in the signs and symptoms of dry eye disease (“DED”) when crossed over to TearCare. These improvements persisted for six months through month twelve without continued Restasis use.

“Phase 2 of the RCT again demonstrates the clinical effectiveness of TearCare. It also shows that effectiveness appears to be the same whether or not a patient has had prior treatment with Restasis, demonstrating that similar results could be expected when TearCare is used as a primary or secondary treatment for DED,” said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences.

Phase 1 of the SAHARA RCT included 345 subjects at 19 sites in 11 states randomized 1:1 to either TearCare or Restasis1. In Phase 2 of the SAHARA RCT, 163 patients who had been randomized and treated with Restasis during phase 1 were crossed over to TearCare at the six-month visit and followed for six months through Month 12 of the study.

Data from the first six months of the SAHARA RCT demonstrated that TearCare, an interventional eyelid procedure for DED, was superior at all measured time points to twice daily use of Restasis for the improvement of tear break up time (“TBUT”), the trial’s primary dry eye signs endpoint and a key measure of tear stability1. TearCare was superior to Restasis in multiple other objective measures of dry eye, and demonstrated clinically meaningful improvements in several symptoms that matched or surpassed Restasis at all measured time points.

The aim of phase 2, undertaken in months six through twelve, was to demonstrate that cessation of Restasis followed by a single TearCare procedure would result in improved signs and symptoms for patients beyond what was achieved with six months of Restasis.

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the results as published in the journal Clinical Ophthalmology of a new analysis of the ROMEO (Retrospective, Observational, Multicenter Evaluation of OMNI) study data. This new analysis evaluated the association between the severity of glaucoma and the intraocular pressure ("IOP") and medication outcomes for patients treated with the OMNI Surgical System ("OMNI"). OMNI enables a procedure intended to restore aqueous outflow of glaucomatous eyes by addressing the three areas of outflow resistance associated with the disease.

The findings suggest that ab interno canaloplasty coupled with trabeculotomy using OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma patients as it was in mild and moderate glaucoma patients. This data challenges the belief that advanced disease stage is a barrier to successful treatment outcomes for minimally invasive glaucoma surgery ("MIGS").

"There had been some debate about the efficacy of MIGS in advanced glaucoma patients, with speculation that prolonged disease may cause irreversible harm to the distal outflow pathway," said Dr. Jaime E. Dickerson, Jr., Vice President of Medical and Clinical Affairs at Sight Sciences. "The current study suggests that treatment with OMNI technology, which has a strong safety profile and proven durability, is still effective in patients with more extensive visual field damage."

ROMEO was an Institutional Review Board ("IRB") approved retrospective case series conducted at eleven ophthalmology practices in the United States. Participants were mainly primary open-angle glaucoma patients (122 of 129, or 95%) who had undergone the implant-free OMNI procedure, which has been cleared by the FDA for canaloplasty followed by ab interno trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma, either combined with cataract surgery or as a standalone procedure.

Eyes were categorized based on visual field mean deviation ("MD"), with participants assigned to a group with severity rated as mild (n=79, median MD -2.7 dB), moderate (n=42, median MD -8.0 dB) or advanced (n=6, median MD -13.3). The study compared outcomes at 12 months.

Key findings reported in the study include:

Significant reductions in both IOP and IOP-reducing medications were observed.
The majority of eyes (70%) experienced a reduction in IOP at Month 12, with most achieving levels of 18 mmHg or less (92%).
The percentage of IOP reduction was consistent across severity groups, with month 12 mean IOP ranging between 14 mmHg and 16 mmHg.
Medication reductions were observed across all severity groups, with the majority of patients showing a reduction of at least 1 medication (50% to 69%), indicating the effectiveness of the treatment approach.
Regression analysis found no significant relationship between month 12 IOP and visual field loss, suggesting treatment outcomes were consistent irrespective of disease severity.
"Clinical trials and real-world results continue to demonstrate favorable OMNI treatment outcomes across different stages of glaucoma," said Paul Badawi, Co-Founder and CEO of Sight Sciences. "These findings reinforce our dedication to offering effective treatment options for glaucoma patients at every stage of the disease and also fuel our initiatives to continue reimagining eyecare with transformative technology and an interventional mindset."

Looking awesome! Excellent quarterly conference call. PPS is strong and the future should be most favorable. +$6 is a few pennies away. +$10 this summer seems reasonable.

Great news!

News of a settlement? Basis for yesterday's gain?
04/23/2024 STATEMENT Offer of Proof Regarding the Economic Comparability of the Glaukos Settlement Agreement by Alcon Inc.,

Beautiful close above $6.

Jury selection begins pretty soon between Alcon and sight sciences. SGHT has very good sales and clinically proven efficacy. Seems to me that the quickest fix for Alcon’s problems is to buy sight sciences, lock, stock, and barrel. Alcon gets two great products and whatever sight sciences has in development. Perhaps most importantly, an acquisition makes Alcon's legal problems go away. Alcon's is looking at huge retroactive and ongoing royalties due to Sight Sciences, if the jury decides against Alcon.

SGHT: The potential expansive applications for their tech. go way beyond mere 'DRY EYES', per se.

SGHT: We'll see what their 'Industry' thinks about it come 4-5-24. (Their Firm is in Menlo Park --- i.e., "Silicon Valley".)

“Long-term data is key in the selection of a surgical treatment,” said Arkadiy Yadgarov, MD, of Omni Eye Services of Atlanta, GA. “The 12-month GEMINI trial demonstrated efficacy of the OMNI procedure combined with cataract surgery for IOP and medication reduction in mild-to-moderate glaucoma.1,2 This extension of the trial shows that these positive 12-month outcomes were sustained through 36 months.”

“In phase 1 of the SAHARA trial, we found the interventional TearCare procedure provided statistically superior and sustained improvement in tear break-up time and multiple measures of meibomian gland secretion when compared to treatment with Restasis.3 In phase 2 (cross-over) of the study, we found that a single TearCare procedure improved signs and symptoms for patients beyond what was achieved with six months of Restasis.”

SGHT: (See their PR, below) Their CEO seems pretty excited about their looming presentation to fix Dry Eye disorder, inter alia.
https://finance.yahoo.com/news/sight-sciences-announces-results-three-200500426.html

Up huge after hours following good news
Can’t wait for tomorrow morning.

Up again

Looking strong. $5

Q will be discussed early March. Now that reimbursement is no longer an issue, blue sky ahead.

Well done sister! Gl

Bought more near $4

Thoughts?
Ill wait this time to see what you think.
Im not feeling it yet on this.

Walk away while you can!

good for you!
I'm holding my 68,000 shares for higher gains.
I wish I put in the same money when I bought shares near $1

68110 shares at $2.98/share

Day Gain
+$55,850.18(+15.92%)
Total Gain
+$203,648.89(+100.34%)

I couldn’t resist.
GL

Sold $5.93

Waiting for news to explain today's big jump.
Going to break $6?

Nice green start to this!

$5.10 loaded

Thoughts on current price?
I have a low bid sitting but you watch this better than I do.

Another good year. I wonder if Q4 showed a downturn due to the possibility of Medicare declining to reimburse. Now that Medicare has confirmed reimbursement I suspect Q1 and beyond will be strong.


https://finance.yahoo.com/news/sight-sciences-announces-preliminary-unaudited-210500004.html

You deserve it!

What an awesome day. Massive volume and up 55%

Big vol and gain. Happy Holidays!

Looking for reversals of mac notifications

MORE GOOD NEWS

https://finance.yahoo.com/news/sight-sciences-announces-publication-successful-210500987.html

Better than 8% up today. New study will resolve reimbursement issues.

https://www.dovepress.com/36-month-outcomes-from-the-prospective-gemini-study-canaloplasty-and-t-peer-reviewed-fulltext-article-OPTH

Up .20 premarket

Staffan Encrantz, an insider of Sight Sciences, Inc., recently acquired 521,855 shares of the company. The buys took place at prices ranging from $3.09 to $3.46 per share, on dates ranging from November 24 to November 28, 2023. Encrantz now owns 6,074,526

I bought back in today.

I'm all out @ $2

Good luck to those who wait for even greener pastures

$2.11 SWEET

About doubled on my latest buys

Up .13 today
Up .05 after hours

Well done.
I jumped on too soon but saw a bit of green on the way out.